Nicox to distribute acute conjunctivitis diagnostic test in Japan

September 3, 2014

Nicox S.A. has entered into an exclusive agreement with Nitto Medic for the distribution in Japan of AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis.

Sophia Antipolis, France-Nicox S.A. has entered into an exclusive agreement with Nitto Medic for the distribution in Japan of AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis.

Nicox has worldwide rights outside North American for the diagnostic test as per an agreement with Rapid Pathogen Screening.

More in this issue: Allergan treatment for DME extended in EU

“We are delighted to sign this agreement with Nitto Medic,” said Michele Garufi, chairman and chief executive officer of Nicox. “We believe that the high accuracy of (the diagnostic test) and its easy-to-use characteristics, together with the relationships of Nitto Medic amongst Japanese ophthalmologists, will contribute to the success of this innovative diagnostic tool.”

Under the terms of the agreement, Nitto Medic will become the exclusive distributor of the diagnostic test in Japan. Nitto Medic will pay a €500,000 upfront payment to Nicox and will purchase the devices from Nicox.

 

Nitto Medic will be responsible for obtaining the relevant regulatory approval in Japan before the launch, which is expected to be within the next 18 months, pending regulatory approval.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.